National Academies Press: OpenBook
« Previous: Workshop Summary
Suggested Citation:"Acronyms." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×

Acronyms

Akt protein kinase B

ALS amyotrophic lateral sclerosis

C-Path Critical Path Institute

caBIG cancer Biomedical Informatics Grid

CEO chief executive officer

CERN European Organization for Nuclear Research

CMS Centers for Medicare & Medicaid Services

EBI European Bioinformatics Institute

EMEA European Medicines Agency

FDA Food and Drug Administration

FDG-PET flurodeoxyglucose-positron emission tomography

FNIH Foundation for the National Institutes of Health

I-SPY 2 TRIAL Inspection of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular analysis 2

IGFR insulin-like growth factor receptor

IMI Innovative Medicines Initiative

IND investigational new drug

IP intellectual property

Suggested Citation:"Acronyms." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×

IRB institutional review board

IT information technology

MEK mitogen-activated protein kinase 1

MIT Massachusetts Institute of Technology

MMRF Multiple Myeloma Research Foundation

MRF Myelin Repair Foundation

NCI National Cancer Institute

NHGRI National Human Genome Research Institute

NIH National Institutes of Health

NME new molecular entity

OBQI Oncology Biomarker Qualification Initiative

OSDD Open Source Drug Discovery

PI3K phosphatidylinositol-3 kinase

PMA premarket approval

R&D research and development

SEMATECH SEmiconductor MAnufacturing TECHnology

START Standard Terms of Agreement for Research Trial

TCGA The Cancer Genome Atlas

UCSF University of California–San Francisco

Suggested Citation:"Acronyms." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×
Page 85
Suggested Citation:"Acronyms." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×
Page 86
Next: Glossary »
Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary Get This Book
×
 Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary
Buy Paperback | $41.00 Buy Ebook | $32.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Despite spending more time and money in developing novel therapeutics, the success rate for new pharmacologic treatments has been poor. Although the research and development expenditures have grown 13 percent each year since 1970 (a 50-fold increase), the number of new drugs approved annually is no greater now than it was 50 years ago. Over the past decade, skyrocketing costs and the complexity of the scientific knowledge upon which to develop new agents have provided incentives for alternative approaches to drug development, if we are to continue to improve clinical care and reduce mortality. These challenges create opportunities for improved collaboration between industry, academia, government, and philanthropic organizations at each stage in new drug development, marketing, and implementation.

Perhaps the most appropriate initial step in addressing the need for collaboration is to consider more precompetitive relationships that allow sharing of scientific information to foster drug development. While these collaborative relationships in basic and preclinical research on drug targets and the early stages of clinical testing are acknowledged to be potentially important drivers for innovation and more rapid marketing of new agents, they also raise a number of concerns that must be addressed. For example, acknowledgment of academic productivity and independence and economic competitiveness must be considered and these challenges managed to foster a culture of collaboration. At the same time, regulatory issues, the need for standardization, and intellectual property concerns must be confronted if the current models for drug development are to be refined to encourage robust participation in precompetitive collaborations.

Recognizing the growing importance of precompetitive collaborations in oncology drug development, as well as the challenges these innovative collaborations pose, the National Cancer Policy Forum of the Institute of Medicine held a workshop on February 9 and 10, 2010. This book is a summary of the workshop proceedings.

READ FREE ONLINE

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!